- TheStreet.com•5 months ago
Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.
- TheStreet.com•10 months ago
TheStreet's Adam Feuerstein answers reader questions about biotech investing.
- Capital Cube•11 months ago
Click here to see latest analysisOncothyreon, Inc. reports financial results for the quarter ended March 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -12.89 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.ONTY-US‘s earnings and EBITDA are both […] (Read more...) The post Oncothyreon, Inc. :ONTY-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 appeared first on CapitalCube.
ONTY : Summary for Oncothyreon Inc. - Yahoo Finance
Oncothyreon Inc. (ONTY)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|